Norman Mack
Overview
Explore the profile of Norman Mack including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
258
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arseni L, Sigismondo G, Yazdanparast H, Hermansen J, Mack N, Ohl S, et al.
Nat Commun
. 2025 Jan;
16(1):1041.
PMID: 39863584
Chronic lymphocytic leukemia is a malignant lymphoproliferative disorder for which primary or acquired drug resistance represents a major challenge. To investigate the underlying molecular mechanisms, we generate a mouse model...
2.
Seiboldt T, Zeiser C, Nguyen D, Celikyurekli S, Herter S, Najafi S, et al.
Br J Cancer
. 2024 Jun;
131(4):763-777.
PMID: 38942989
Background: Certain paediatric nervous system malignancies have dismal prognoses. Retinoic acid (RA) is used in neuroblastoma treatment, and preclinical data indicate potential benefit in selected paediatric brain tumour entities. However,...
3.
Brinkmann B, Floerchinger A, Schniederjohann C, Roider T, Coelho M, Mack N, et al.
Blood
. 2024 May;
144(7):784-789.
PMID: 38805637
Relapse after anti-CD19 chimeric antigen receptor (CD19-CAR) occurs in a substantial proportion of patients with lymphoid malignancies. We assessed the potential benefits of co-administering CD20-targeting bispecific antibodies (CD20-BsAbs) with CD19-CAR...
4.
Arseni L, Sharma R, Mack N, Nagalla D, Ohl S, Hielscher T, et al.
Cancers (Basel)
. 2023 Jan;
15(2).
PMID: 36672428
Glioblastoma is the most aggressive brain tumor in adults. Treatment failure is predominantly caused by its high invasiveness and its ability to induce a supportive microenvironment. As part of this,...
5.
Hanna B, Llao-Cid L, Iskar M, Roessner P, Klett L, Wong J, et al.
Immunity
. 2021 Dec;
54(12):2825-2841.e10.
PMID: 34879221
T cell exhaustion limits anti-tumor immunity and responses to immunotherapy. Here, we explored the microenvironmental signals regulating T cell exhaustion using a model of chronic lymphocytic leukemia (CLL). Single-cell analyses...
6.
Simovic M, Bolkestein M, Moustafa M, Wong J, Korber V, Benedetto S, et al.
Neuro Oncol
. 2021 May;
23(12):2028-2041.
PMID: 34049392
Background: Medulloblastomas with chromothripsis developing in children with Li-Fraumeni Syndrome (germline TP53 mutations) are highly aggressive brain tumors with dismal prognosis. Conventional photon radiotherapy and DNA-damaging chemotherapy are not successful...
7.
Haag D, Mack N, da Silva P, Statz B, Clark J, Tanabe K, et al.
Cancer Cell
. 2021 Feb;
39(3):407-422.e13.
PMID: 33545065
Diffuse intrinsic pontine glioma (DIPG) is an aggressive childhood tumor of the brainstem with currently no curative treatment available. The vast majority of DIPGs carry a histone H3 mutation leading...
8.
Kutscher L, Okonechnikov K, Batora N, Clark J, Silva P, Vouri M, et al.
Genes Dev
. 2020 Aug;
34(17-18):1161-1176.
PMID: 32820036
Medulloblastoma is a malignant childhood brain tumor arising from the developing cerebellum. In Sonic Hedgehog (SHH) subgroup medulloblastoma, aberrant activation of SHH signaling causes increased proliferation of granule neuron progenitors...
9.
Lambo S, Grobner S, Rausch T, Waszak S, Schmidt C, Gorthi A, et al.
Nature
. 2019 Dec;
576(7786):274-280.
PMID: 31802000
Embryonal tumours with multilayered rosettes (ETMRs) are aggressive paediatric embryonal brain tumours with a universally poor prognosis. Here we collected 193 primary ETMRs and 23 matched relapse samples to investigate...
10.
Pajtler K, Wei Y, Okonechnikov K, Silva P, Vouri M, Zhang L, et al.
Nat Commun
. 2019 Sep;
10(1):3914.
PMID: 31477715
YAP1 fusion-positive supratentorial ependymomas predominantly occur in infants, but the molecular mechanisms of oncogenesis are unknown. Here we show YAP1-MAMLD1 fusions are sufficient to drive malignant transformation in mice, and...